The "Keytruda Market Size, Share & Trends Analysis Report By Application (Lung Cancer, Breast Cancer, Melanoma, Hodgkin Lymphoma), By Payer (Commercial/Private, Public), By Distribution Channel, By ...

A potential U.S. launch of this Chinese biotech's new lung cancer drug - which bested Merck's blockbuster Keytruda - is a key ...

Learn more about whether Moderna, Inc. or Roivant Sciences Ltd. is a better investment based on AAII's A+ Investor grades, which compare both companies' key financial metrics.

Learn more about whether Moderna, Inc. or Protagonist Therapeutics, Inc. is a better investment based on AAII's A+ Investor ...

Over the past week, Merck's share price has decreased by 5.42%, slightly exceeding the broader market's decline. The combination of these shareholder ... knowledge and a deep understanding of product ...

The report forecasts global market growth from $116.1 billion in 2024 to $168 billion by 2029 at a CAGR of 7.7%. Highlighting advances in immunothera ...

In a phase 2 trial, an antiretroviral combination developed by Gilead Sciences ... said Gilead and MSD, known as Merck & Co in the US and Canada. Patients in the study were switched to the regimen ...

Hopefully a new standard of care for the aggressive disease, according to partners Gilead Sciences and Merck & Co ... line therapy for the cancer in combination with chemotherapy, in patients ...

TOKYO, Japan & MUNICH, Germany I April 08, 2025 I DATROWAY® (datopotamab deruxtecan) has been approved in the European Union (EU) for the treatment of ...

Limits of Inherent Anticipation in Product-by-Process Claims - In Restem, LLC v. Jadi Cell, LLC, Appeal No. 23-2054, the Federal Circuit held ...

In April 2025, Janssen Research & Development, LLC announced a study is to evaluate the efficacy, including clinical ...

North America Cancer Therapy Market Size Set Expands at Significant CAGR of 8.15% During 2024-2030 to Reach USD 5.87 Billion by 2030 Request To Download Free Sample of This Strategic Report @ ...